> Bioinformatics 2004 > - Industry Impact and Outlook - > 26th & 27th May 2004, Marriott Kensington, London > > Effective use of bioinformatic systems can drastically > reduce drug discovery and development timescales > * By using information technology and software tools > to analyse gene sequences, genotypes that correspond > to certain medical conditions may be identified. > * Informatics can then lead to the discovery of potential > molecular targets and subsequently the development > and design of drugs far more rapidly than previously possible. > Bioinformatics 2004 will provide a unique overview of > the technologies available and in development: > Book early to secure your place - mailto:[EMAIL PROTECTED] > > Key themes will include: > * In depth analysis and strategies to improve information-flow > * Tactics for knowledge management and evolution of innovative informatic > solutions > * Finding the best ways to handle e-clinical data and upcoming > opportunities in this market > * Data analysis and integration: pointers on data mining, in silico > research and use of informatic tools > * Case studies of informatic systems: learn from leaders in the industry > * Current market and outlook: genomics, proteomics and pharmacogenomics > > Industry Leading speakers confirmed at this event: > * Dr. Mark Swindells, Chief Scientific Officer, Inpharmatica > * Dr. Charlie Hodgman, Chair of Bioinformatics, Uni. Nottingham & > Midlands Centre for Integrative Biology & Senior Informatics Leader, GSK > * Dr Luca Casareto, Director Bioinformatic Solutions, Informax > * Robin Clark, Managing Consultant, IBM Business Consulting Services > * Dr. Krister Kristianson, Director of Clinical Research, Merck > * Hani Kamel, Quality and Security Advisor, Novo Nordisk > * Dr. Richard Scott, Director of Technology Development, De Novo > Pharmaceuticals > * Kevin Wandryk, VP Marketing & Business Development, Silicon Genetics > * Dr. Ulrich Meier, Industry Marketing Manager Life Sciences, Sun > Microsystems > * Dr. Kal Ramnarayan, Vice President and CSO, Cengent Therapeutics > * Thure Etzold, Senior VP Bioinformatics, LION Bioscience > * David Lovell, Reader in Medical Statistics, University of Surrey & > Associate Director, European Head of Statistical Support to Clinical > Pharmacology, Pfizer > > Who Should attend? (by job title) > * Global Head, Informatics & Knowledge Management > * Director of Medical Informatics > * Director of Discovery Research Informatics > * Head of Advanced Computing > * Head of Global IT Management > * Head/ Director of Bioinformatics > * Head of Datamining and Visualisation > * Senior Informatics Leader > * Head of Life Science Informatics > * Senior Scientist, Genomic Collaborations > * European Applications Specialist > * Director, Discovery Bioinformatics > * European Manager, Statistics & Information Science > * Director, IT Discovery Pharmaceuticals > * Director, Global Information Solutions > * Head of Informatics > > Please find below the conference agenda. To book your place at > Bioinformatics 2004 simply give me a quick ring or email me > stating whether you require a single place or a group booking > > - PRICING - > Attend the: > ** Conf. + pre conf. workshop GBP 1600.00 Plus VAT > ** Conference only Fee: GBP1299.00 Plus VAT > ** Pre conference workshop only Fee: GBP 650.00 Plus VAT > > - BOOKINGS - > Booking is easy, simply contact Lorraine Lescure on: > Telephone: +44 (0)20 8767 6711 > Fax: +44 (0)20 8767 5001 > Email: mailto:[EMAIL PROTECTED] > Terms and conditions apply - see below. > I look forward to hearing from you soon. > > Regards, > > Lorraine Lescure > Account Manager > Visiongain b2b Conferences > Tel: +44 (0) 20 8767 6711 > http://www.b2b-conferences.com > mailto:[EMAIL PROTECTED] > > > Sponsorship Opportunities > This event will provide unrivalled opportunities to promote your brand to an > audience of senior level delegates. Decision makers from all aspects> of the > Bioinformatics industry will be in attendance, what better way to elevate > your product? We are continually recognised for providing innovative and > effective means to support your marketing requirements through sponsorship > and exhibitions at our leading events. > Options include: > * Full Conference Sponsorship > * Exhibition Stand/Booth > * Promotional Inserts > * Delegate Bag Sponsor > * Cocktail Reception Sponsor > Whatever your budget, whatever your requirements we can find you a way to > place your brand at Bioinformatics 2004. > > > > ***Agenda*** > > > Pre-Conference Interactive Workshop > Successful Licensing and Business Development > Tuesday 25th May 2004 > > Workshop Leaders: Mrs. Sharon Finch and Prof. Bill Dawson, Medius Associates > > Topics Under discussion: > * Logistics and planning the due diligence process > * Scientific and regulatory due diligence > * Intellectual property rights, legal and corporate due diligence > * Commercial and financial issues > * Logistics- planning and negotiation > * Preparation > * Understanding the third party > * Team roles and negotiation styles > * Negotiation tactics > > > DAY 1 Wednesday 26th May 2004 > > Conference Chairman > David Lovell > Reader in Medical Statistic > University of Surrey > > 9:00 Registration and coffee > > 9:30 Opening remarks from the Chair > > STRATEGIC PLANNING > > 9:40 How to Transform Data into Commercially Valuable > Information > *> Overcoming challenges faced by the pharmaceutical industry > *> Key organisational strategies: meeting the needs of the > pharmaceutical vs biotech > *> What is the optimal structure for informatics in R&D? > *> How to use informatic services to facilitate drug discovery and > development > *> A guide to transforming sequence data into validated drug targets > Dr. Mark Swindells > Chief Scientific Officer > Inpharmatica > > 10:20 Aiding Business Strategy: An Information-Flow Model > *> Model: structured map of pharmaceutical information, depicting > issues faced > *> Strategies for reducing costs through portfolio management and > interconnectivity > *> Proposals for using information mechanisms for increased > efficiency > *> Model for biotech: > - where a novel technology might impact upon and improve the > R&D process > - where can service/ information providers position themselves for > maximum benefit > *> Key thinking for business development > Dr. Charlie Hodgman > Chair of Bioinformatics > Uni. Nottingham and Directorship of the Midlands Centre > for Integrative Biology > > 11:00 Morning Coffee > > 11:20 Pointers for Choosing the Best Partnership for You > *> Licensing out products following pre-clinical development > *> How to identifying the correct product to license in > *> Gaining or giving access to technologies, which will be the best for > you? > *> Recommendations on which route to take: comparison of different > agreements > Panel Discussion and Questions > > KNOWLEDGE MANAGEMENT > > 12:00 Procedures in Driving Data Workflow Integration for > Effective Information Management > *> How to alleviate the bottlenecks in the life science pipeline > - better investment in tools and applications > *> Can better integration techniques ease the burden of delivering > faster processes? > *> Large bioinformatic systems versus integrated discrete solutions > *> Informax bioinformatics solutions for workflow optimisation and > pipeline integration > Dr Luca Casareto > Director > Bioinformatic Solutions > Informax > > 12:40 Lunch > > DATA ANALYSIS AND INTEGRATION > > 14:00 In silico Research: How it can link your Drug Discovery to > Development > *> Advantages of in silico drug trials > *> The future of simulation modelling of drug trials > *> How to use in silico tools for reliable property prediction and > rational chemical design > *> Potential enhancement of the overall R&D productivity > *> Challenges of in silico biology technology for tomorrow > Dr. Richard Scott> > Director of Technology Development > De Novo Pharmaceuticals > > 14:40 Informatics Software Market: Breaking Constraints and > Handling Competition > *> Area sectors: specialising in software packages for visualising, > interpreting and analysing data > *> How to overcome constraints of this niche market > - limited number of customers > - diverse informatic needs of clients > *> How to handle direct competition > - free or publicly available software and tools > - direct competition from academic institutions > - small startups v large companies > Kevin Wandryk > VP Marketing & Business Development > Silicon Genetics > > 15:20 Afternoon Tea > > HANDLING E-CLINICAL DATA > > 15:40 Strategies for Reducing the Time and Cost of Running Trials, > whilst increasing the Quality of Data > *> Difficulties faced in drug development > *> Turning challenges to opportunities > *> How to simplify and automate trial processes, for example: > - by transforming trial management > - taking EDC to the next level > - implementing an efficient archival strategy > *> A holistic approach to clinical data > Robin Clark > Managing Consultant > IBM Business Consulting Services > > 16:20 Questions and Discussion > > 16:40 Close of Day One > > DAY 2 Thursday 27th May 2004 > > Conference Chairman > David Lovell > Reader in Medical Statistic > University of Surrey > > 9:00 Registration and Coffee > > 9:30 Opening remarks from the chair > > 9:40 Electronic Medical Records or e-source: how to cut your > monitoring cost in half by no more SDV, no more data entry > no missed data > *> EMR's - a challenge to the conduct of clinical trials > *> How to deal with its rapid entry into the hospital and medical > records > *> Increased complications in the access to the source: security and > privacy of the hospital system > *> How to use opportunities in the market > Dr. Krister Kristianson > Director of Clinical Research > Merck > > 10:20 Data Standards and the FDA: Overcoming the Challenges > Associated with E-Clinical Trials > *> Evaluating FDA acceptance of new technologies in clinical trials > *> Implementation of e-signatures > *> Reconciliation with HL7 standards > *> Using clinical data interchange standards for the development of > e-clinical trials > Charles Jaffe > Director of Medical Informatics > AstraZeneca > > 11:00 Morning Coffee > > 11:20 Key Tactics to Enhance Global Data Security > *> Meeting universal requirements: what regulatory problems could > arise? > *> Overcoming the scientific problems that can arise from poor > security > *> Recommendations for enabling global security to fit unobtrusively > into the clinical environment > *> Proposals to ensure clinical data security over the web > Hani Kamel > Quality and Security Advisor > Novo Nordisk > > PRACTICAL BIOINFORMATICS: IN THE INDUSTRY > > 12:00 CASE STUDY: Grid Computing and its Impact on Your > Network > *> Grid computing solutions- tackles complex computer intensive > tasks quickly and cost-effectively > *> Three basic deployment types: cluster grids, enterprise grids, and > global grids > *> What benefits do grids delivery that traditional computing models > are not able to? > *> Sun's bio-grid strategy > *> Sun infrastructure solutions: transforming technology into business > results > *> Deploying grid computing for a competitive advantage > Dr. Ulrich Meier > Industry Marketing Manager > Life Sciences > Sun Microsystems > > 12:40 Lunch > > 14:00 CASE STUDY: Accelerating Your Drug Discovery with Genes > to Leads > *> How can genes to leads deliver selective hits in as little as 60 > days? > *> Key differentiators from alternative drug discovery approaches > *> Features and benefits of proprietary technology > *> Success in discovering potent small-molecule leads for anthrax > infection and PTP1B > *> Genes to Leads success summary > Dr. Kal Ramnarayan > Vice President and CSO > Cengent Therapeutics > > 14:40 CASE STUDY: SRS Gateway for Oracle, Reducing the> > Challenges for the Life Science Industry > *> SRS and the oracle database > *> What are the benefits of combining the power of two industry-leading > platforms > *> Experience of SRS collaborations, the SRS evolution > *> The drive for drug discovery, a working progress > Thure Etzold > Senior VP Bioinformatics > LION Bioscience > > 15:20 Afternoon Tea > > PROTEOMICS > > 15:40 Managing Collection, Analysis and Interpretation of Data > from Functional Proteomics > *> Data from functional proteomics: how to effectively and efficiently > manage it > *> Statistical input into the design, analysis and interpretation of > functional proteomic studies > *> Achieving synergy between bioinformatics and statistics > *> Linking analysis of pharmacogenomic data into drug discovery and > development > David Lovell > Reader in Medical Statistics > University of Surrey > > 16:20 Questions and Discussion > > 16:40 Chairman Summation > > 16:50 Close of Conference > > > > > > > > Visiongain/B2B Conferences produce a range of timely business information > material, if you wish to receive information of new products, simply reply to > this email with ' New Products info' in the subject box > > > > > > > > > > > Terms & Conditions > NB - Due to high demand, we do not 'reserve' or 'hold' places - a request for > an invoice to be raised will be treated as an official booking and will be > subject to the cancellation policy as outlined below. > Cancellations/substitutions and name changes: All bookings carry a 50% > liability after the booking has been made, by post fax, email or web. There > will be no refunds for cancellations received on or after one month before > the start of the conference (e.g. cancellation on or after 20th January for a > conference starting on 20th February). If you decide to cancel after this > date the full invoice remains payable. Conference notes, which are available > on the day, will be sent to you. Unfortunately we are not able to transfer > places between conferences and executive briefings. However if you are unable > to attend the event you may make a substitution/name change at any time as > long as we are informed in writing by e-mail, fax or post. Name changes and > substitutions must be from the same company and are not transferable between > companies or countries. > > Indemnity: visiongain Ltd reserve the right to change the > conference/executive briefing content, timing, speakers or venue without > notice. The event may be postponed or cancelled due to acts of terrorism, > war, extreme weather conditions, industrial action, acts of God or any event > beyond the control of visiongain Ltd. If such a situation arises we will > endeavour to reschedule the event. However, visiongain Ltd cannot be held > responsible for any cost, damage or expenses, which may be incurred by the > customer as a consequence of the event being postponed or cancelled. We > therefore strongly advise all customers to take out insurance to cover the > cost of the registration, travel and expenses. > To unsubscribe please reply with unsubscribe in the subject line. > Data protection: Visiongain Ltd gathers and manages data in accordance with > the Data Protection Act 1998. Information contained about you may be used to > update you on visiongain Ltd products and services via post, telephone, fax > or email, unless you state otherwise. We may share your data with external > companies offering complimentary products or services. If you wish your > details to be amended, suppressed or not passed onto any external third > party, please send your request to the Database Manager, visiongain Ltd, 40 > Tooting High Street, London, SW17 0RG. Alternatively, you can visit our > website www.visiongain.com <<http://www.visiongain.com/>> and amend your > details. Please allow approximately 30 days for your removal or update > request, you may receive additional pieces of communication from visiongain > Ltd during the transitional period, whilst the changes come into effect.> > > > > > > #####################################################################################
This email has been scanned by MailMarshal, an email content filter. #####################################################################################
